Financial Advisors Network Inc. increased its stake in Humana Inc (NYSE:HUM) by 26.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,836 shares of the insurance provider’s stock after buying an additional 383 shares during the period. Financial Advisors Network Inc.’s holdings in Humana were worth $455,000 as of its most recent SEC filing.
A number of other hedge funds also recently bought and sold shares of the stock. WFG Advisors LP increased its stake in Humana by 4.5% in the 2nd quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock worth $113,000 after buying an additional 20 shares during the period. Scotia Capital Inc. increased its stake in Humana by 4.8% in the 2nd quarter. Scotia Capital Inc. now owns 2,200 shares of the insurance provider’s stock worth $529,000 after buying an additional 100 shares during the period. Advantus Capital Management Inc increased its stake in Humana by 1.4% in the 3rd quarter. Advantus Capital Management Inc now owns 14,798 shares of the insurance provider’s stock worth $3,605,000 after buying an additional 203 shares during the period. Cadence Capital Management LLC increased its stake in Humana by 3.6% in the 3rd quarter. Cadence Capital Management LLC now owns 5,887 shares of the insurance provider’s stock worth $1,434,000 after buying an additional 205 shares during the period. Finally, Daiwa SB Investments Ltd. increased its stake in Humana by 44.9% in the 4th quarter. Daiwa SB Investments Ltd. now owns 710 shares of the insurance provider’s stock worth $176,000 after buying an additional 220 shares during the period. 94.13% of the stock is currently owned by institutional investors.
Humana Inc (NYSE:HUM) opened at $265.32 on Monday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.85 and a quick ratio of 1.61. Humana Inc has a 12-month low of $203.36 and a 12-month high of $293.35. The stock has a market cap of $36,528.92, a P/E ratio of 15.91, a PEG ratio of 1.44 and a beta of 0.93.
Humana declared that its Board of Directors has initiated a share repurchase program on Thursday, December 14th that permits the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization permits the insurance provider to reacquire shares of its stock through open market purchases. Shares repurchase programs are often an indication that the company’s leadership believes its shares are undervalued.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 27th. Stockholders of record on Friday, March 30th will be given a $0.50 dividend. The ex-dividend date of this dividend is Wednesday, March 28th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.75%. This is an increase from Humana’s previous quarterly dividend of $0.40. Humana’s payout ratio is presently 9.59%.
In other news, VP Timothy S. Huval sold 1,382 shares of Humana stock in a transaction that occurred on Tuesday, December 19th. The shares were sold at an average price of $246.04, for a total value of $340,027.28. Following the transaction, the vice president now owns 11,557 shares of the company’s stock, valued at approximately $2,843,484.28. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Jody L. Bilney sold 7,054 shares of Humana stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $247.89, for a total transaction of $1,748,616.06. Following the completion of the transaction, the senior vice president now directly owns 11,704 shares in the company, valued at approximately $2,901,304.56. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,115 shares of company stock worth $2,501,627. Insiders own 0.80% of the company’s stock.
HUM has been the topic of a number of research reports. BMO Capital Markets initiated coverage on shares of Humana in a research report on Monday, October 16th. They set an “outperform” rating and a $300.00 target price on the stock. Zacks Investment Research downgraded shares of Humana from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Credit Suisse Group initiated coverage on shares of Humana in a research report on Thursday, November 2nd. They set a “neutral” rating and a $256.00 target price on the stock. Royal Bank of Canada reissued a “sector perform” rating and set a $242.00 target price (down previously from $245.00) on shares of Humana in a research report on Thursday, November 9th. Finally, Morgan Stanley cut their target price on shares of Humana from $276.00 to $270.00 and set an “overweight” rating on the stock in a research report on Thursday, November 9th. Eight equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $270.63.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.